Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.
Journal: Neuro-oncology
Published: February 25, 2021
Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 08, 2019
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: May 22, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Journal: The Lancet. Oncology
Published: February 06, 2019
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 02, 2017
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
Journal: Journal of the National Cancer Institute
Published: February 18, 2015
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.
Journal: Breast cancer research and treatment
Published: December 02, 2012
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 11, 2012
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 03, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026